Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Ranitidine did not show higher cancer risk than famotidine in study

Key clinical point: Cancer diagnoses were seen in people who took H2 drugs, compared with the general population, but the people taking ranitidine and famotidine also had more oncologic risk factors.

Major finding: Incidence of cancer was respectively 14.69%, 21.24%, and 5.38% for the ranitidine group, the famotidine group, and the group representing the general population without use of either H2 blocker.

Study details: This cohort study drew comparisons based on medical records for 65 million people.

Disclosures: No outside funding was used for the study.


Mohyuddin N et al. DDW 2020. Abstract Tu1360.